Skip to main content

Table 5 Adjusted mean body plethysmography outcomes at 6 weeks: IC and FRC (full analysis set)

From: Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies

   

IC

FRC

Treatment

Planned time (min)

na

Mean (SE) IC, L

Mean (SE) difference from placebo, L

p value

Mean (SE) FRC, L

Mean (SE) difference from placebo, L

p value

Study 1222.37

      

Placebo

−30 (pre-dose/trough)

134-135

2.170 (0.040)

  

4.977 (0.062)

  

Olodaterol 5 μg

 

139-140

2.289 (0.040)

0.119 (0.034)

0.0005

4.855 (0.061)

−0.122 (0.069)

0.0784

Olodaterol 10 μg

 

134

2.262 (0.040)

0.092 (0.034)

0.0073

4.862 (0.062)

−0.115 (0.070)

0.1013

Placebo

60 (post-dose)

134-135

2.221 (0.040)

  

4.950 (0.064)

  

Olodaterol 5 μg

 

139-140

2.427 (0.040)

0.206 (0.035)

<0.0001

4.740 (0.063)

−0.210 (0.066)

0.0015

Olodaterol 10 μg

 

134

2.437 (0.040)

0.216 (0.036)

<0.0001

4.577 (0.064)

−0.373 (0.066)

<0.0001

Study 1222.38

      

Placebo

−30 (pre-dose/trough)

147

2.463 (0.041)

  

4.842 (0.062)

  

Olodaterol 5 μg

 

145-146

2.613 (0.041)

0.150 (0.040)

0.0002

4.757 (0.063)

−0.086 (0.053)

0.1048

Olodaterol 10 μg

 

141-142

2.618 (0.042)

0.154 (0.040)

0.0001

4.723 (0.063)

−0.120 (0.053)

0.0246

Placebo

60 (post-dose)

147

2.493 (0.040)

  

4.770 (0.065)

  

Olodaterol 5 μg

 

145-146

2.725 (0.040)

0.232 (0.036)

<0.0001

4.557 (0.065)

−0.213 (0.053)

<0.0001

Olodaterol 10 μg

 

141-142

2.696 (0.040)

0.203 (0.036)

<0.0001

4.583 (0.065)

−0.187 (0.054)

0.0005

  1. aN numbers for IC and FRC
  2. IC inspiratory capacity, FRC forced residual capacity, SE standard error